Educational Barriers Are Still Holding Back Biosimilars

Experts Shared Views On Biosimilar Uptake At A Sandoz Webinar

Panellists at a recent webinar hosted by Sandoz on “unlocking the potential of biosimilars” agreed that biologics are increasingly advancing to first-line treatments. However, industry and regulatory leaders cited lack of education as a significant barrier to biosimilars uptake. The experts also offered reasons for the reduced uptake in immunology biosimilars compared to oncology. 

Information
Industry and regulatory leaders acknowledged the lack of proper education on biosimilars • Source: Alamy

A recent webinar on “unlocking the potential of biosimilars” organized by Sandoz Inc. and Reuters saw industry and regulatory leaders voice their opinions on how to encourage biosimilar uptake based on lessons learned from 15 years of biosimilars in Europe, including through greater efforts on education.

“We see now that biologics have advanced from third to second, even to first line treatments or earlier patient access,”...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.